Patrick Baeuerle - Sep 8, 2021 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Acting Chief Scientific Officer, Biologics
Signature
/s/ Jeffrey Trigilio, Attorney-in-Fact
Stock symbol
CGEM
Transactions as of
Sep 8, 2021
Transactions value $
-$265,650
Form type
4
Date filed
9/9/2021, 04:15 PM
Previous filing
Aug 26, 2021
Next filing
Feb 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Options Exercise $47.3K +11K $4.30 11K Sep 8, 2021 Direct
transaction CGEM Common Stock Sale -$313K -11K -100% $28.45 0 Sep 8, 2021 Direct F1
holding CGEM Common Stock 341K Sep 8, 2021 See Footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Options Exercise $0 -11K -4.38% $0.00 240K Sep 8, 2021 Common Stock 11K $4.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021.
F2 Shares held directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
F3 25% of the shares vested on September 1, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Acting Chief Scientific Officer, Biologics